Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F List

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Seminars in Oncology|August 1, 1996
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicityA F List, R Heaton, B Glinsmann-Gibson, et al.
Leukemia|October 10, 1998
Amifostine stimulates formation of multipotent and erythroid bone marrow progenitorsA F List, R Heaton, B Glinsmann-Gibson, et al.
Leukemia Research|February 5, 1999
Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndromeA M Miller, W E Noyes, R Taetle, et al.
The American Journal of Medicine|February 1, 1991
Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease accelerationA F List, G Gonzalez-Osete, T Kummet, et al.
Leukemia Research|May 19, 1998
Treatment with low-dose oral etoposide in patients with myelodysplastic syndromesD C Doll, L M Kasper, R Taetle, et al.
The Annals of Pharmacotherapy|February 1, 1995
Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipientsP E Kintzel, C J Rollins, W J Yee, et al.
The American Journal of Medicine|September 1, 1990
Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphateA F List, T D Kummet, J D Adams, et al.
Leukemia|March 1, 1993
Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetenceA F List, C M Spier, T P Miller, et al.
Transfusion Medicine (Oxford, England)|June 15, 2007
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004P Fenaux, J M Bennett, D T Bowen, et al.
Leukemia Research|October 13, 2009
JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clonesL Sokol, G Caceres, K Rocha, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Seminars in Oncology|August 1, 1996
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicityA F List, R Heaton, B Glinsmann-Gibson, et al.
Leukemia|October 10, 1998
Amifostine stimulates formation of multipotent and erythroid bone marrow progenitorsA F List, R Heaton, B Glinsmann-Gibson, et al.
Leukemia Research|February 5, 1999
Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndromeA M Miller, W E Noyes, R Taetle, et al.
The American Journal of Medicine|February 1, 1991
Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease accelerationA F List, G Gonzalez-Osete, T Kummet, et al.
Leukemia Research|May 19, 1998
Treatment with low-dose oral etoposide in patients with myelodysplastic syndromesD C Doll, L M Kasper, R Taetle, et al.
The Annals of Pharmacotherapy|February 1, 1995
Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipientsP E Kintzel, C J Rollins, W J Yee, et al.
The American Journal of Medicine|September 1, 1990
Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphateA F List, T D Kummet, J D Adams, et al.
Leukemia|March 1, 1993
Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetenceA F List, C M Spier, T P Miller, et al.
Transfusion Medicine (Oxford, England)|June 15, 2007
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004P Fenaux, J M Bennett, D T Bowen, et al.
Leukemia Research|October 13, 2009
JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clonesL Sokol, G Caceres, K Rocha, et al.
Pageof 10